Interestingly, preclinical data show that β-catenin is activated by EGFR-mutants and contributes to the development of EGFR-mutated NSCLC, so that CTNNB1-mutations can potentially induce resistance to EGFR-TKIs [41–43]. Here, EGFR is linked to non-small cell lung carcinoma.